HIF1A Gene Function
Hypoxia Inducible Factor 1 Subunit Alpha
Overview
HIF1A encodes the oxygen-sensitive subunit of HIF-1, the master transcription factor for hypoxic adaptation. Under low oxygen, HIF1α escapes VHL-mediated degradation and activates genes for glycolysis, angiogenesis, and erythropoiesis.
Molecular Mechanism
Mechanism Summary
Under normoxia, PHD enzymes hydroxylate HIF-1α at Pro402/Pro564, enabling VHL-E3 ligase recognition and rapid proteasomal degradation. Hypoxia inhibits PHDs (O2-dependent), stabilising HIF-1α to activate VEGFA, glycolytic enzymes, and survival genes.
Step-by-Step Mechanism
In normoxia (>3% O2), prolyl hydroxylase domain (PHD) enzymes (PHD1/2/3) hydroxylate HIF-1α at Pro402 and Pro564 using O2 and 2-oxoglutarate as co-substrates, producing hydroxy-Pro-HIF-1α.
Hydroxy-Pro-HIF-1α is recognised by VHL (von Hippel-Lindau protein), which serves as the substrate-recognition component of an E3 ubiquitin ligase (VHL–elongin C–elongin B–CUL2–RBX1). HIF-1α is polyubiquitinated and degraded by the 26S proteasome within minutes.
In hypoxia (<1% O2) or when PHDs are inhibited, HIF-1α escapes hydroxylation and accumulates in the cytoplasm. It translocates to the nucleus and heterodimerises with HIF-1β (ARNT) via PAS domain interactions.
HIF-1α/HIF-1β heterodimer recruits the co-activators p300/CBP (via HIF-1α C-TAD interaction) and binds hypoxia-response elements (HREs: RCGTG) in target gene promoters, activating transcription.
HIF-1 target genes include VEGFA (angiogenesis), GLUT1/GLUT3 (glucose import), HK2/LDHA (glycolysis), PDK1 (mitochondrial pyruvate oxidation inhibition), BNIP3 (mitophagy), and EPO (erythropoiesis in kidney).
Factor inhibiting HIF (FIH/HIF1AN) hydroxylates Asn803 in HIF-1α C-TAD under normoxia, blocking p300/CBP interaction and providing a second oxygen-sensing mechanism. This site is less sensitive to hypoxia than Pro402/564.
In clear cell renal carcinoma (VHL-mutant), constitutive HIF-1/2α activation drives VEGFA, PDGFB, and CXCR4 expression independent of oxygen, creating a normoxic pseudohypoxic state that drives angiogenesis and immune evasion.
Upstream Regulators
O2-dependent Pro hydroxylation targeting HIF-1α for VHL degradation; primary O2 sensor
E3 ligase substrate adaptor; loss causes constitutive HIF activation
Enhances HIF-1α mRNA cap-dependent translation; creates hypoxia-PI3K synergy
Downstream Targets
Tumour angiogenesis; endothelial cell recruitment
Aerobic glycolysis (Warburg effect)
Mitophagy; mitochondrial clearance in hypoxia
pH regulation; immune evasion marker
Key Post-Translational Modifications
VHL recognition → ubiquitination → degradation (normoxic destruction)
Blocks p300/CBP C-TAD interaction; reduces transcriptional output
Enhanced VHL interaction; promotes degradation
Disease Mechanism
Biallelic VHL loss is a defining feature of many clear cell renal cell carcinomas and prevents normal oxygen-dependent degradation of HIF-α subunits. HIF-2α has a particularly important disease role and can be directly inhibited by belzutifan. Regulatory indications have changed over time and should be checked in current prescribing information; HIF1A and HIF2A biology should not be treated as interchangeable.
Database References
Key Pathways
- ·HIF-1 signaling pathway
- ·Hypoxia response
- ·Angiogenesis
- ·Glycolysis/Warburg effect
Disease Associations
- ·Solid tumor hypoxia
- ·Polycythemia
- ·Pulmonary hypertension
Functional Partners
Common Questions About HIF1A
What does HIF1A do in cancer?
HIF-1α is the oxygen-sensing subunit of HIF-1 that, under tumour hypoxia, drives transcription of VEGFA for angiogenesis, GLUT1 and HK2 for glycolysis, and invasion genes. It essentially reprogrammes tumour metabolism and vasculature to support survival and growth in low-oxygen conditions.
How does VHL regulate HIF-1α?
In normoxia, prolyl hydroxylase domain (PHD) enzymes hydroxylate two prolines in HIF-1α, enabling recognition by the VHL E3 ubiquitin ligase for proteasomal degradation. Hypoxia inhibits PHDs (which require oxygen), stabilising HIF-1α. VHL mutations in clear cell renal carcinoma constitutively activate HIF-1/2α even in normoxia.
What is the Warburg effect and how does HIF1A drive it?
The Warburg effect describes cancer cells preferring aerobic glycolysis — producing lactate even with abundant oxygen. HIF-1α transcriptionally upregulates glycolytic enzymes (LDHA, HK2, PKM2) and PDK1, which inhibits mitochondrial pyruvate oxidation. This metabolic shift meets the biosynthetic demands of rapid proliferation.
Is HIF1A a drug target?
Belzutifan inhibits HIF-2α rather than HIF-1α and has FDA-labelled uses that must be checked in the current prescribing information. VEGF- or VEGFR-directed therapies act farther downstream and have tumour-specific indications. PHD inhibitors used in anaemia alter oxygen-sensing biology for a different clinical purpose and should not be presented as cancer treatments.